About

Company description

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and global reliable supply. Our team of nearly 13,000, including approximately 2,400 scientists at over 35 sites, develops more than 700 projects and helps launch over 200 products every year. We produce +72 billion doses of +7,000 products for more than 1,000 customers – or 1 in 20 doses taken by patients globally. We partner with 87 of the top 100 global pharmaceutical marketers, to 24 of 25 biological marketers, to 21 of 25 leading consumer health marketers, to thousands of small innovators globally. Our passion is to help unlock the full potential of your product.

More products better treatments reliably supplied ™


Quick facts

Sales markets Western Europe; Eastern Europe; Asia; Australia; North America; Central/South America
Affiliated categories: Analytical Development |Antibody Drug Conjugates (ADCs) |API Contract Manufacturing More

Upcoming events

5 may 2020

CPhI North America 2020

5 - 7 May 2020 Philadelphia, USA Visit us at stand 1301 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 121A82 See our Exhibitor Profile   See full Exhibitor List
30 apr 2019

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA We were at stand 1206 See our Exhibitor Profile   See full Exhibitor List
9 oct 2018

CPhI Worldwide 2018

9 - 11 October 2018 Madrid, Spain We were at stand 3D10 See our Exhibitor Profile   See full Exhibitor List

News about Catalent

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

4 Dec 2019

Catalent to Partner with Ethicann on new fast-dissolve cannabinoid-based treatment

Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.

Read more

13 Nov 2019

Catalent's new launch improves titers and cell-specific productivity

GPEx Boost has been shown to improve titers up to four-fold.

Read more

6 Sep 2019

Catalent to open new clinical supply facility in San Diego

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more

19 Jun 2019

Catalent to purchase BMS manufacturing facility

Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.

Read more
Catalent

Contact information

Address

Telephone

Website

View all contact information